Abacus dx Cancer Diagnostics – Breast Cancer
Breast cancer is the most common cancer affecting women in Australia and New Zealand1 and the second most commonly diagnosed cancer in Australia2. The estimated number of new cases of breast cancer diagnosed in 2019 for Australia was 19,535 and 3,504 for New Zealand1. The number of women diagnosed with breast cancer is expected to increase each year due to the ageing population1. What else can be done to improve lab workflow and confidence in your results?
Cell Marque™ Immunohistochemistry markers
Traditional markers such as E-cadherin and p120 Catenin are significant markers used in the detection of breast carcinomas, specifically aiding in the differentiation of lobular and ductal carcinoma of the breast.
E-cadherin is expressed in a membranous pattern in ductal carcinomas while p120 Catenin expression can be found in lobular carcinomas in the cell cytoplasm and not in the cell membrane.
HistoCyte breast cancer controls
We are pleased to offer you the HistoCyte product range to add a higher level of trust and ease for your breast cancer testing. Antibodies like ER, PR, and HER2 can require stringent grading standards, and sometimes ideal control tissue is difficult to find- especially in the case of HER2 with 2+ expression.
The Dynamic Range blocks from HistoCyte show the full range of expression, including a negative osteosarcoma control. They can be used with IHC and ISH. These are actually cell blocks that were expertly developed to maintain the morphological characteristics of tissue.
Below is an example of of HER2 antibody stained with IHC and ISH on the HistoCyte HER2 dynamic range block.
ZytoVision ERBB2 Probe for use in breast cancer prognosis
The proto-oncogene ERBB2 is amplified in approximately 20% of all breast cancers and is correlated with a poor prognosis1. Breast cancer patients harbouring ERBB2 amplification are addressed for a targeted therapy with trastuzumab (Herceptin®), a humanized monoclonal antibody directed against the extracellular portion of the ERBB2 protein. This treatment is associated with significantly prolonged overall survival and time of tumor progression2.
The ZytoLight® SPEC ERBB2/CEN 17 Dual Color Probe is designed for the detection of ERBB2 (a.k.a HER2) gene amplification frequently observed in solid malignant neoplasms e.g. breast cancer samples.
1. Brown-Glabermann U, et al. (2014) Oncology (Williston Park) 28: 281-9.
2. Bourdeanu L & Luu T (2014) J Adv Pract Oncol 5: 246-60.